Results 21 to 30 of about 172 (100)

Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Methotrexate (MTX) has been a longstanding therapeutic option for mycosis fungoides (MF); however, data on its real‐world effectiveness remain limited. This study aimed to assess real‐world outcomes of oral MTX in the treatment of MF. Data from five referral centres for cutaneous lymphoma in Greece were retrospectively reviewed with the baseline‐ and ...
Vasiliki Nikolaou   +21 more
wiley   +1 more source

Application experience of extracorporeal photopheresis for treatment of acute “graft-versus-host” disease after allogeneic hematopoietic stem cell transplantation

open access: yesОнкогематология, 2014
Extracorporeal photopheresis (ECP) has been used as a component of combined immunosuppressive therapy in 53 patients with steroid-refractoryacute “graft-versus-host” disease.
A. V. Kozlov   +6 more
doaj   +3 more sources

OF PHOTOPHERESIS IN KIDNEY TRANSPLANTATION

open access: yesВестник трансплантологии и искусственных органов, 2018
Aim – to perform a comparative study of the long-term results of the combined use of extracorporeal photochemotherapy (photopheresis) and drug immunosuppression and standard immunosuppressive therapy in patients after kidney transplantation.Materials and
A. P. Faenko   +6 more
doaj   +1 more source

A survey of extracorporeal photopheresis treatment in pediatric patients in the United Kingdom

open access: yeseJHaem, 2020
Extracorporeal photopheresis (ECP) is a second‐line therapy in acute and chronic GVHD and solid organ transplant rejection. We report ECP use in 98 pediatric patients in seven UK centers from 2010 to 2017, the majority treated for aGVHD (73.5%).
Aisling M. Flinn   +12 more
doaj   +1 more source

Should we use extracorporeal photopheresis more often? Evidence from graft-versus-host disease patients monitored with Treg as a biomarker

open access: yesFuture Science OA, 2020
Background: Chronic graft-versus-host disease (cGvHD) is a major complication after allogeneic hematopoietic cell transplantation. Extracorporeal photopheresis (ECP) is an immunotherapy treatment for cGvHD, although suitable response biomarkers are ...
Sérgio Machado Lopes   +7 more
doaj   +1 more source

Models for plasma kinetics during simultaneous therapeutic plasma exchange and extracorporeal membrane oxygenation [PDF]

open access: yesarXiv, 2020
This paper focuses on the derivation and simulation of mathematical models describing new plasma fraction in blood for patients undergoing simultaneous extracorporeal membrane oxygenation and therapeutic plasma exchange. Models for plasma exchange with either veno-arterial or veno-venous extracorporeal membrane oxygenation are considered.
arxiv  

Management challenge of a rare concomitant platelet glycoprotein IV/CD36 and IIb/IIIa deficiencies: Case illustration

open access: yesTransfusion, Volume 65, Issue 4, Page 767-772, April 2025.
Abstract Introduction/Background Platelet membrane glycoproteins (GPs) serve several functions, the most significant of which is their role in primary hemostasis. Among these, GP IIb/IIIa is the primary fibrinogen receptor and is essential for platelet aggregation.
Tro Sekayan   +8 more
wiley   +1 more source

Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure

open access: yesHaematologica, 2014
Second-line therapy for corticosteroid-refractory or -dependent acute graft-versus-host disease remains ill-defined, due to limited efficacy of drugs and evolving clinical trial endpoints.
Emma Das-Gupta   +10 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis   +16 more
wiley   +1 more source

Extracorporeal photopheresis for the treatment of chronic graft versus host disease

open access: yesHematology, 2022
Objectives Chronic graft versus host disease (chronic GVHD) still remains the leading cause of late morbidity and mortality for allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients.
Emin Kansu   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy